EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sensitive circulating tumor DNA–based residual disease detection in epithelial ovarian cancer

Heini Ml Kallio iD, Kalle Savolainen iD, Tuomo Virtanen, Lauri Ryyppö, Hanna Selin, Päivi Martikainen, Synnöve Staff, Kati Kivinummi iD, Joonatan Sipola, Juuso Vuorinen, Jussi Nikkola iD, Matti Nykter und 2 weitere

Life Science Alliance · 2024-06 · 7 (6) · e202402658

DOI: 10.26508/lsa.202402658 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 05.04.2024. Verfasst von Heini Ml Kallio und 13 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Ovarian Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jane and Aatos Erkko Foundation, Academy of Finland Center of Excellence Programme, Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epithelial ovarian cancer (EOC) is one of the leading causes of cancer-related death in women worldwide, and is characterized by a high rate of recurrence after surgery and chemotherapy. We sought to implement a circulating tumor DNA (ctDNA)–based blood test for more accurate post-operative surveillance of this disease. We analyzed 264 plasma samples collected between June 2016 and September 2021 from 63 EOC patients using tumor-guided plasma cell-free DNA analysis to detect residual disease after treatment. Assay specificity was verified using cross-patient analysis of 1,195 control samples. ctDNA was detected in 51 of 55 (93%) samples at diagnosis, and 18 of 18 (100%) samples at progression. Positive ctDNA in the last on-treatment sample was associated with rapid progression (median 1.02 versus 3.38 yr, HR = 5.63, P < 0.001) and reduced overall survival (median 2.31 versus NR yr, HR = 8.22, P < 0.001) in patients with high-grade serous cancer. In the case of 12 patients, ctDNA assays detected progression earlier than standard surveillance, with a median lead time of 5.9 mo. To approach the physical limits of ctDNA detection, five patients were analyzed using ultra-sensitive assays interrogating 479–1,856 tumor mutations, capable of tracking ctDNA fractions down to 0.0004%. Our results demonstrate that ctDNA assays achieve high sensitivity and specificity in detecting post-operative residual disease in EOC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAOvarian NeoplasmsHumansFemaleCarcinoma, Ovarian EpithelialNeoplasm Recurrence, Local

Substanzen

Circulating Tumor DNA

Autor:innen und Institutionen

  • Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
  • Department of Obstetrics and Gynecology, Tays Cancer Centre, Tampere University Hospital, Tampere, Finland.
  • Department of Urology, Tampere University Hospital, Tampere, Finland.
  • Department of Obstetrics and Gynecology, Tays Cancer Centre, Tampere University Hospital, Tampere, Finland annika.auranen@pirha.fi.
  • Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland matti.annala@tuni.fi.

ORCID-Profile: Heini Ml Kallio, Kalle Savolainen, Kati Kivinummi, Jussi Nikkola, Annika Auranen, Matti Annala

Förderung

  • Jane and Aatos Erkko Foundation
  • Academy of Finland Center of Excellence Programme
  • Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital
  • Finnish Cultural Foundation
  • TAYS Foundation

Zitieren

APA

Kallio, H. M., Savolainen, K., Virtanen, T., Ryyppö, L., Selin, H., Martikainen, P., Staff, S., Kivinummi, K., Sipola, J., Vuorinen, J., Nikkola, J., Nykter, M., Auranen, A., & Annala, M. (2024). Sensitive circulating tumor DNA–based residual disease detection in epithelial ovarian cancer. Life Science Alliance, 7(6), e202402658. https://doi.org/10.26508/lsa.202402658

Vancouver

Kallio HM, Savolainen K, Virtanen T, Ryyppö L, Selin H, Martikainen P, et al. Sensitive circulating tumor DNA–based residual disease detection in epithelial ovarian cancer. Life Science Alliance. 2024;7(6):e202402658. doi:10.26508/lsa.202402658

BibTeX
@article{Kallio2024,
  author = {Kallio, Heini Ml and Savolainen, Kalle and Virtanen, Tuomo and Ryyppö, Lauri and Selin, Hanna and Martikainen, Päivi and Staff, Synnöve and Kivinummi, Kati and Sipola, Joonatan and Vuorinen, Juuso and Nikkola, Jussi and Nykter, Matti and Auranen, Annika and Annala, Matti},
  title = {Sensitive circulating tumor DNA–based residual disease detection in epithelial ovarian cancer},
  journal = {Life Science Alliance},
  year = {2024},
  volume = {7},
  number = {6},
  pages = {e202402658},
  doi = {10.26508/lsa.202402658}
}
Kostenlos starten →